Joe Stephenson, MD
Hematology & Oncology · Greenville, SCNPI 1346245552
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,655 of the $57,026 with a category attached, or 73.0%. Pfizer accounts for 68.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $21,556 and has fallen 98.6% since, to $299 in 2025. Among hematology & oncology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 186 payments — averaging $306.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$39K
- Novartis$15K
- E.r. Squibb & Sons, L.L.C.$323
- Amgen$313
- Merck$308
- Bayer$281
- plus $2K from 32 others
Across 9 payments — averaging $163.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1K
- Eli Lilly$38
What the payments were for
- Consulting fees$8,73515%
- Speaking & faculty fees$41,65573%
- Travel & lodging$9982%
- Food & beverage$3,6836%
- Education$4411%
- Other$1,5153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 51 | $39,129 |
| Novartis | 33 | $14,534 |
| E.r. Squibb & Sons, L.L.C. | 4 | $323 |
| Amgen | 4 | $313 |
| Merck | 11 | $308 |
| Bayer | 8 | $281 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $212 |
| Eisai Inc. | 9 | $182 |
| Gilead(2 entities) | 7 | $179 |
| AstraZeneca | 6 | $167 |
| Ipsen Biopharmaceuticals, Inc | 1 | $145 |
| Rigel Pharmaceuticals, Inc. | 2 | $145 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $140 |
| Incyte Corporation | 2 | $115 |
| Daiichi Sankyo Inc. | 5 | $110 |
| Seagen Inc. | 5 | $105 |
| Bristol Myers Squibb | 4 | $72 |
| Alnylam Pharmaceuticals Inc. | 3 | $61 |
| Lilly USA, LLC | 3 | $56 |
| Springworks Therapeutics, Inc. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $45 |
| Genentech USA, Inc. | 2 | $35 |
| Beigene USA, Inc. | 2 | $35 |
| Medtronic | 1 | $31 |
| Genmab U.S., Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $22 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| G1 Therapeutics, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,026 in reported general payments places this provider in the 95th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 47 | $684,857 |
| XtandiEnzalutamide | 42 | $579,542 |
| IbrancePalbociclib | 24 | $382,158 |
| PomalystPomalidomide | 11 | $252,528 |
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $198,618 |
| TafinlarDabrafenib Mesylate | 11 | $159,924 |
| DopteletAvatrombopag Maleate | 12 | $138,533 |
| BrukinsaZanubrutinib | 11 | $95,058 |
| PromactaEltrombopag Olamine | 17 | $75,387 |
| Abiraterone Acetate | 51 | $57,490 |
| Imatinib Mesylate | 37 | $11,551 |
| Exemestane | 78 | $11,386 |
| Tamoxifen Citrate | 217 | $5,335 |
| Anastrozole | 286 | $4,856 |
| Letrozole | 124 | $1,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Mekinist, Tafinlar, Promacta | $14,534 | $1,118,78688 claims |
| Astellas Pharma US IncXtandi | $45 | $579,54242 claims |
| PfizerIbrance | $39,129 | $382,15824 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $323 | $252,52811 claims |
| Beigene USA, Inc.Brukinsa | $35 | $95,05811 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $19 | $57,49051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Elizabeth CullGreenville$16K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
- Ming LimCharleston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.